1-8 of 8
Daniel B. Costa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Daniel B. Costa, Michael S. Rabin, Nikhil Wagle, Lynette M. Sholl, Pasi A Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4072–4079.
https://doi.org/10.1158/1078-0432.CCR-20-0397
Published: 03 August 2020
View articletitled, Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Open the PDF for Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2277.
https://doi.org/10.1158/1078-0432.CCR-20-0939
Published: 01 May 2020
View articletitled, Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Journal Articles

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6548–6555.
https://doi.org/10.1158/1078-0432.CCR-18-1541
Published: 13 December 2018
View articletitled, EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Magda Bahcall, Mark M. Awad, Lynette M. Sholl, Frederick H. Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia C. Leonardi, Bryan C. Ulrich, Cloud P. Paweletz, Paul T. Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J. Nagy, Richard B. Lanman, Marzia Capelletti, Emily S. Chambers, Amanda J. Redig, Paul A. VanderLaan, Daniel B. Costa, Yu Imamura, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5963–5976.
https://doi.org/10.1158/1078-0432.CCR-18-0876
Published: 03 December 2018
View articletitled, Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Open the PDF for Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6010–6020.
https://doi.org/10.1158/1078-0432.CCR-16-0909
Published: 15 December 2016
View articletitled, A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Open the PDF for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial in another window
Includes: Supplementary data
Journal Articles

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

Stephanie Heon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4406–4414.
https://doi.org/10.1158/1078-0432.CCR-12-0357
Published: 14 August 2012
View articletitled, The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
Open the PDF for The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations in another window
Journal Articles

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (23): 5873–5882.
https://doi.org/10.1158/1078-0432.CCR-10-1588
Published: 06 December 2010
View articletitled, Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Open the PDF for Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib in another window
Journal Articles

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Daniel B. Costa, Kim-Son H. Nguyen, Byoung C. Cho, Lecia V. Sequist, David M. Jackman, Gregory J. Riely, Beow Y. Yeap, Balázs Halmos, Joo H. Kim, Pasi A. Jänne, Mark S. Huberman, William Pao, Daniel G. Tenen, Susumu Kobayashi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7060–7067.
https://doi.org/10.1158/1078-0432.CCR-08-1455
Published: 03 November 2008
View articletitled, Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Open the PDF for Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib in another window